Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Other Routine +

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

By The Northwire Desk — AI Analysis Jun 01, 2026 · 07:30 BCT · 5.03 BRIACELL THERAPEUTICS CORP. J
Executive Summary
  • BriaCell Therapeutics presented final Phase 2 survival data and ongoing Phase 3 biomarker/quality-of-life updates at ASCO 2026 on June 1, 2026.
  • Final Phase 2 data for the Phase 3 formulation shows a median overall survival (OS) of 16.6 months, with >55% survival at 12 months and >27% at 24 months.
  • Safety profile remains excellent with no treatment-related discontinuations across the 32-patient Phase 2 cohort.
  • Ongoing Phase 3 blinded data confirms preserved quality of life, favorable TWiST outcomes, and validates biomarker correlations: stable/decreased CAML counts significantly correlate with improved progression-free survival (PFS).
  • CPI initiation timing shows a stark survival differential: median OS of 13.3 months when started in Cycle 1 versus 7.4 months in Cycle 2.
  • DTH-positive patients demonstrated a median OS of 11.9 months versus 4.7 months for DTH-negative patients.
  • The company also announced a $4.7 million best-efforts public offering priced at $3.25 per share on May 31, 2026, to fund working capital and advance business objectives.
  • Historical progression from October 2025 through May 2026 shows consistent DSMB safety endorsements, steady Phase 3 enrollment (>230 patients), FDA Fast Track maintenance, and incremental platform expansions (Bria-BRES+, Bria-PROS+, Bria-OVA+).
Material Impact
  • The ASCO 2026 data is incremental and aligns with previously disclosed trends from SABCS, ESMO, and AACR presentations. The ~16.6-month median OS and strong safety profile confirm the earlier Phase 2 trajectory but do not represent a paradigm-shifting breakthrough or regulatory milestone.
  • Biomarker validation (CAMLs, DTH, CTCs) supports future patient stratification but remains unproven in the blinded Phase 3 readout.
  • The $3.25 share pricing is dilutive and reflects market pricing for a low-float clinical-stage biotech, but the capital raise is routine for funding ongoing Phase 3 operations.
  • No new partnerships, licensing deals, or FDA approval pathways were announced. The data reinforces the existing thesis without materially altering the risk/reward profile or valuation drivers.
  • The news is expected, follows a clear historical progression, and lacks the surprise element required for a material positive rating.
BCT · Price
Company Overview
  • BriaCell Therapeutics is a clinical-stage biotechnology company developing personalized, off-the-shelf whole-cell cancer immunotherapies.
  • Flagship program: Bria-IMT combined with an immune checkpoint inhibitor (CPI) for heavily pre-treated metastatic breast cancer (MBC), currently in a pivotal Phase 3 trial (Bria-ABC).
  • The therapy activates both innate and adaptive immunity, targeting CD8+ T cells, NK cells, and dendritic cells.
  • Pipeline expansion includes Bria-BRES+ (breast cancer), Bria-PROS+ (prostate cancer), and Bria-OVA+ (ovarian cancer), all leveraging the next-generation Bria-OTS+ platform.
  • The company holds FDA Fast Track designation for the Bria-IMT + CPI regimen, reflecting significant unmet medical need in late-stage MBC.
Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other May 22, 2026 · 07:30

ASCO Data Confirms Survival Benefit Amidst Dilution Headwinds

Other